Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the effectiveness of adding RCP (redensyl, capixyl, procapil) to a hair loss treatment regimen that includes minoxidil and finasteride. Users share experiences, suggesting RCP may not be as effective as minoxidil, but could be useful for creating topical solutions.

The user experienced noticeable hair regrowth after three months of using topical minoxidil and finasteride, with no reported side effects. Other users discussed their experiences with similar treatments, including concerns about side effects and alternative options like dutasteride.

Breezula (clascoterone) Phase 3 hair loss trial results are delayed, with no official updates yet. The acne version is approved, but hair loss results are still pending.

A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.

A user shared their positive 3-month experience using finasteride, minoxidil, and vitamin D to treat hair loss, noting significant regrowth and minimal shedding. They also discussed potential side effects and the low likelihood of experiencing them, while being open to answering further questions.

The user experienced improved hair health and density after three months using 1mg finasteride and topical minoxidil twice daily, with no side effects. They also use ketoconazole 2% twice weekly and purchase their medications from Amazon.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly suggests the creation of a new chemical called RU99999.

Kintor's KX826 (pyrilutamide) is ineffective at 0.5% and overpriced at 1%, leading to user frustration and calls for fair pricing. Users suggest sticking with proven treatments like Minoxidil and Finasteride.

The user experienced significant hair maintenance using 0.25mg daily finasteride and minoxidil foam, with minimal side effects. They recommend oral finasteride for better results, especially for the crown area.

A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.

The user reported using 1.1 mg finasteride, 5 mg minoxidil, 1 mg biotin, dermastamping twice a week, and Nizoral shampoo and anti-itch liquid. The replies praised the progress and suggested a follow-up at six months.

The conversation discusses hair loss treatments, focusing on a new slow-release oral minoxidil compared to topical minoxidil and finasteride. The results show that twice-daily dosing of the new treatment is slightly more effective than once-daily, but concerns about cost, side effects, and the accuracy of reported results remain.

MCL-1 is important for hair follicle stem cell survival, but its impact on human hair regrowth is unclear. Minoxidil and finasteride are the main treatments, with doubts about new discoveries leading to effective human solutions soon.

The conversation is about seeking updates on the hair loss treatment RCH-01, specifically its next phase and any news from Shiseido. The user recalls someone being in contact with a researcher or company representative.

The conversation discusses hair loss treatments, with the original poster considering joining a clinical trial for setipiprant after experiencing side effects from finasteride and disinterest in minoxidil. Some users express skepticism about setipiprant's effectiveness, while others encourage participation in the trial for potential benefits.

A user is seeking a European supplier for a 3-in-1 hair loss medication containing Minoxidil, Finasteride, and Biotin. Suggestions include using forwarding services and a UK-based provider, with discussions on potential import taxes.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

The user improved their hair loss from stage 5 to stage 3 using Minoxidil, Finasteride, and a Dermapen. They saw results after 6 months, experienced a shedding phase, then saw more gains, advising others not to be discouraged during the shedding phase.

The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.

A user is considering switching to a topical treatment containing finasteride, minoxidil, and tretinoin, instead of their current regimen of oral finasteride and oral minoxidil. They are unsure whether to try the new topical or continue with their current treatment.

The conversation is about a user who experienced hair growth after three months of using Minoxidil and plans to start Finasteride soon. The user is considering a hair transplant next year and is curious about the potential for further growth.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

A user shared progress pictures showing significant hair regrowth after 3 months using a topical foam with 5% Minoxidil and 0.25% Finasteride. They plan to add derma rolling to their routine.

A 33-year-old male has been using topical finasteride, Minoxidil, RU58841, keto, and derma stamp for hair loss treatment for 3 months. He is optimistic about the promising results.

The user shared 6-month results using finasteride, minoxidil, ketoconazole shampoo, vitamin D, calcium, and biotin, showing significant improvement. Another user praised the results as excellent.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

A user is considering adding PRP and mesotherapy to their hair loss treatment and is deciding between two options: Promoitalia, which contains Phosphatidic acid, Riboflavin, and Superoxide dismutase, and the more expensive Melsmon, a human placenta derivative. They seek advice on which option to choose based on effectiveness and scientific backing.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

A satirical post humorously discusses a fictional hair regrowth drug called PP405, with users joking about its effectiveness and bizarre presentation. The conversation includes humorous reactions and references to the absurdity of the content.

Norwood 7 hair loss is often excluded from trials to ensure treatments appear more effective and to reduce costs. Some believe treatments effective for Norwood 5 could work on Norwood 7, but companies prioritize market readiness.